PhinC Development
PhinC Development specializes in quantitative pharmacology solutions, including modeling and simulation, to optimize drug development processes. With a focus on supporting small and medium-sized pharmaceutical and biotech companies, they offer tailored services such as integrated phase 1 solutions, physiologically-based pharmacokinetic modeling, population pharmacokinetics, and more. Their mission is to support drug development through innovative, model-informed approaches, fostering efficiency, safety, and regulatory compliance.
Industries
Nr. of Employees
small (1-50)
PhinC Development
Products
SimMabs research project (monoclonal antibody modelling)
Research project focused on advancing modelling approaches for monoclonal antibodies and biologics to support translational and regulatory needs.
PBPK–ADMET collaborative integration (project)
Collaborative initiative to combine ADMET experimental data with PBPK prediction workflows to enhance exposure and toxicity predictions.
SimMabs research project (monoclonal antibody modelling)
Research project focused on advancing modelling approaches for monoclonal antibodies and biologics to support translational and regulatory needs.
PBPK–ADMET collaborative integration (project)
Collaborative initiative to combine ADMET experimental data with PBPK prediction workflows to enhance exposure and toxicity predictions.
Services
Tailored consulting and operational support to accelerate biotech Phase I trials, combining translational modelling, dose strategy and early clinical decision‑making.
Building and applying PBPK models to translate nonclinical ADME data to human exposure predictions and to support regulatory and development decisions.
Development, validation and application of population PK/PD models to quantify variability, support dose selection and inform clinical program design.
Quantitative analyses to evaluate potential PK interactions and to inform clinical study planning and regulatory strategy.
Model‑based analysis of cardiac safety endpoints to support early‑phase safety assessment.
Comprehensive PK statistical studies and NCA to derive exposure metrics and interpret bioanalytical results.
Tailored consulting and operational support to accelerate biotech Phase I trials, combining translational modelling, dose strategy and early clinical decision‑making.
Building and applying PBPK models to translate nonclinical ADME data to human exposure predictions and to support regulatory and development decisions.
Development, validation and application of population PK/PD models to quantify variability, support dose selection and inform clinical program design.
Quantitative analyses to evaluate potential PK interactions and to inform clinical study planning and regulatory strategy.
Model‑based analysis of cardiac safety endpoints to support early‑phase safety assessment.
Comprehensive PK statistical studies and NCA to derive exposure metrics and interpret bioanalytical results.
Expertise Areas
- Model‑Informed Drug Development (MIDD)
- Physiologically‑Based Pharmacokinetics (PBPK)
- Population pharmacokinetics (PopPK)
- Pharmacokinetic/Pharmacodynamic (PK/PD) modeling
Key Technologies
- Physiologically‑based pharmacokinetic (PBPK) modelling
- Population / nonlinear mixed‑effects modelling
- Quantitative systems pharmacology (QSP)
- Machine learning and AI for predictive modelling
News & Updates
FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
The FDA is replacing animal testing with human-relevant methods to improve drug safety and reduce costs.
An article discussing the importance of PBPK modeling in drug development.
FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
The FDA is replacing animal testing with human-relevant methods to improve drug safety and reduce costs.
An article discussing the importance of PBPK modeling in drug development.